Venrock Funds Hold 5.7% Of OnKure's Class A Shares Under Passive Ownership Disclosure
The position spans funds and a co-investment entity in a drug developer whose programs remain in clinical trials or discovery.
Venrock Healthcare Capital Partners III's reporting group held a 5.7% stake in OnKure Therapeutics, which develops precision medicines for cancer and other hard-to-treat diseases. The group reported 2,309,559 Class A shares as of Friday, November 13, in a passive ownership disclosure filed Friday.
The Funds Behind The Position
Venrock Healthcare Capital Partners EG held 1,154,776 shares, the largest holding within the group's position. Venrock Healthcare Capital Partners III held 1,049,696, and VHCP Co-Investment Holdings III, the group's co-investment entity, held 105,087.
The reporting persons shared voting authority over the aggregate position. VHCP Management III oversees Venrock Healthcare Capital Partners III as its general partner and manages the co-investment entity. VHCP Management EG is the general partner of Venrock Healthcare Capital Partners EG.
Nimish P. Shah and Bong Y. Koh are voting members of both management entities. The aggregate ownership figure covers the group's holdings; the underlying shares sit in the funds and co-investment entity.
The group certified that it neither bought nor holds the securities to change or influence OnKure's control. Its 5.7% calculation used the 40,503,094 Class A shares OnKure reported outstanding on November 2 in its quarterly report filed November 4.
OnKure's Mutation-Targeting Drug Pipeline
OnKure's medicines are designed to inhibit mutated versions of PI3Kα, a protein that drives disease, while leaving its normal form alone. The company is still in clinical development and has no products approved for sale.
Its lead candidate, OKI-219, targets the H1047R mutation. An early-stage trial is testing the drug in patients with solid tumors, including breast cancer, at sites across the United States, European Union and Asia.
OnKure is also pursuing a discovery program aimed at several common PI3Kα mutations and another focused on vascular malformations. The company says it retains worldwide rights to every program.
Sources
- SCHEDULE 13G — Venrock Healthcare Capital Partners III, L.P. re: OnKure Therapeutics, Inc. (OKUR) — SEC EDGAR